Delving into the Latest Updates on Interferon alfa-n3 with Synapse

Overview

Basic Info

Drug Type

Interferons

Synonyms

interferon alfa-n3 (human leukocyte derived), Alferon N

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists)

Therapeutic Areas

Infectious Diseases

Active Indication

Human Papillomavirus Infection

Inactive Indication

HIV InfectionsSevere Acute Respiratory Syndrome

Originator Organization

AIM ImmunoTech, Inc.

Active Organization

AIM ImmunoTech, Inc.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

US (10 Oct 1989),

Human Papillomavirus Infection

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 453129449

Sequence Code 167544

Sequence Code 32821

To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection. The primary endpoints of the study will include an increase or upregulation in genes known to be mediators of interferon response. Secondary endpoints will include the absolute CD4 count and plasma HIV RNA levels.

Start Date01 Jul 2005

Sponsor / Collaborator

AIM ImmunoTech, Inc.

NCT00215826 / CompletedPhase 2

A Randomized, Dose-ranging Study of Alferon® LDO {Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)} in Normal Volunteers and/or Asymptomatic Subjects With Exposure to a Person Known to Have SARS or Possible SARS

The purpose of this trial is to conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an antiviral and immunomodulator in asymptomatic subjects with recent exposure to a person with severe acute respiratory syndrome (SARS) or possible SARS. The primary objective of this pilot study is to determine an Alferon LDO dose level that increases or upregulates genes known to be mediators of interferon response. Secondary endpoints include the development of SARS symptomatology, rate of hospitalization, and mortality rate. In the event that no subjects with recent exposure to a person with SARS or possible SARS are available, this study will be conducted with 10 normal volunteers.

Start Date01 Nov 2004

Sponsor / Collaborator

AIM ImmunoTech, Inc.

100 Clinical Results associated with Interferon alfa-n3

Login to view more data

100 Translational Medicine associated with Interferon alfa-n3

Login to view more data

100 Patents (Medical) associated with Interferon alfa-n3

Login to view more data

25

Literatures (Medical) associated with Interferon alfa-n3

01 Oct 2014·Antiviral ResearchQ2 · MEDICINE

Protection from pulmonary tissue damage associated with infection of cynomolgus macaques by highly pathogenic avian influenza virus (H5N1) by low dose natural human IFN-α administered to the buccal mucosa

Q2 · MEDICINE

Article

Author: Thoolen, Robert J M M ; Strayer, David R ; Stittelaar, Koert J ; Stouch, Bruce C ; Osterhaus, Albert D M E ; Mitchell, William M ; Carter, William A

Using an established nonhuman primate model for H5N1 highly pathogenic influenza virus infection in humans, we have been able to demonstrate the prophylactic mitigation of the pulmonary damage characteristic of human fatal cases from primary influenza virus pneumonia with a low dose oral formulation of a commercially available parenteral natural human interferon alpha (Alferon N Injection®). At the highest oral dose (62.5IU/kg body weight) used there was a marked reduction in the alveolar inflammatory response with minor evidence of alveolar and interstitial edema in contrast to the hemorrhage and inflammatory response observed in the alveoli of control animals. The mitigation of severe damage to the lower pulmonary airway was observed without a parallel reduction in viral titers. Clinical trial data will be necessary to establish its prophylactic human efficacy for highly pathogenic influenza viruses.

01 Feb 2014·Expert Review of Anti-infective TherapyQ2 · MEDICINE

Emergence of a novel drug resistant H7N9 influenza virus: evidence based clinical potential of a natural IFN-α for infection control and treatment

Q2 · MEDICINE

Article

Author: Wenjun Ma ; Jingjiao Ma ; William M Mitchell ; Juergen A Richt ; Qinfang Liu ; William A Carter ; David R Strayer

The novel avian H7N9 influenza virus has caused more than 130 human infections with 43 deaths (as of September, 2013) in China. Because of the lack of existing immunity against H7 subtype influenza viruses in the human population and the absence of a licensed commercial vaccine, antiviral drugs are critical tools for the treatment of infection with this novel H7N9. Both M2-ion channel blockers and neuraminidase inhibitors are used as antiviral drugs for influenza infections of humans. The emerging H7N9 viruses are resistant to the M2-ion channel blockers because of a S31N mutation in the M2 protein; additionally, some H7N9 isolates have gained neuraminidase R292K substitution resulting in broad resistance to neuraminidase inhibitors. In this study we report that Alferon N can inhibit wild type and 292K H7N9 viruses replication in vitro. Since Alferon N is approved for clinical use, this would allow a rapid regulatory approval process for this drug under pandemic threat.

01 Mar 2012·Journal of Interferon & Cytokine ResearchQ4 · MEDICINE

Recombinant and Natural Human Interferons: Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies

Q4 · MEDICINE

Review

Author: Strayer, David R. ; Carter, William A.

This review summarizes and analyzes the clinical outcomes following treatment of a wide range of diseases with recombinant interferons (r-IFNs) and/or natural interferons (n-IFNs). The investigation focuses on the frequency of neutralizing antibodies (NABs) directed against IFN, which are formed during treatment and their clinical impact. r-IFNs (α-2a, α-2b, β-1a, and β-1b) induced seroconversion with generation of NABs in 17.2% of patients studied. The highest incidence of NABs occurred in macular degeneration (61.4%) with the lowest in multiple sclerosis (14.7%). The incidence of antibodies induced against n-IFNs was very low (<0.2%) and was significantly less than that seen for r-IFNs (P<0.0001). Overall, the fraction of relapsed and refractory patients is statistically greater in NAB positive patients compared to NAB negative patients (<0.0001), whereas the percentage of responding patients is higher in the NAB negative cohort (P<0.001). Finally, we also analyzed relapsed and refractory NAB positive patients who switched treatment to n-IFN, such as leukocyte derived Alferon N Injection® (α-n3) or Wellferon® (α-n1). Overall, in 33/40 (82%) of these relapsed or refractory patients, switching to n-IFNs restored the clinical response. This result is consistent with serology studies showing that the NABs directed against r-IFNs do not effectively cross-react with n-IFNs.

100 Deals associated with Interferon alfa-n3

Login to view more data